Description: OKYO Pharma Limited (Nasdaq: OKYO, LSE: OKYO) is a biotechnology company developing next-generation therapeutics to improve the lives of patients suffering from inflammatory eye diseases and ocular pain. OKYO’s research program is focused on a novel G Protein-Coupled Receptor, or GPCR, which OKYO believes plays a key role in the pathology of these inflammatory eye diseases of high unmet medical need. OKYO’s therapeutic approach is focused on targeting inflammatory and pain modulation pathways that drive these conditions. The Company is presently developing OK-101, its lead preclinical product candidate, for the treatment of dry-eye disease “DED”. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis.
Home Page: www.okyopharma.com
OKYO Technical Analysis
55 Park Lane
London,
W1K 1NA
United Kingdom
Phone:
44 20 7495 2379
Officers
| Name | Title |
|---|---|
| Dr. Gary S. Jacob Ph.D. | CEO & Exec. Director |
| Mr. Michael Paul Beck | Founder |
| Ms. Keeren Shah | Chief Financial Officer |
| Dr. Rajkumar Patil Ph.D. | Chief Scientific Officer |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 12.9133 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2022-05-17 |
| Fiscal Year End: | March |
| Full Time Employees: | 7 |